Piramal Pharma
Piramal Pharma reported a transitional FY26 with revenue decline due to inventory destocking in a key on-patent commercial product, subdued biotech funding in H1, and intensified competition in inhalation anesthesia i...
Piramal Pharma vs Raymond Lifestyle Q4 FY26
Side-by-side earnings comparison across verified financials, sentiment, risks, and management commentary.
Raymond Lifestyle
Raymond Lifestyle delivered a strong FY26 with total income of ₹7,034 crore (+11% YoY) and EBITDA of ₹804 crore (+23% YoY), marking the highest ever.
Result Snapshot
Revenue₹2,752 Cr₹1,776 Cr
PAT₹-9 Cr₹-52 Cr
EBITDA Margin—7%
Sentimentneutralbullish
Key Quotes
We're currently anticipating revenue growth in the early to mid teens with EBITDA expected to grow faster than revenue supported by operating leverage.
We crossed 7,000 cr recording our highest ever total income of 7034 crores and 11% year-on-year growth.